Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.

Assoun S, Theou-Anton N, Nguenang M, Cazes A, Danel C, Abbar B, Pluvy J, Gounant V, Khalil A, Namour C, Brosseau S, Zalcman G.

Lung Cancer. 2019 Jun;132:65-71. doi: 10.1016/j.lungcan.2019.04.005. Epub 2019 Apr 8.

PMID:
31097096
2.

NDR2 kinase contributes to cell invasion and cytokinesis defects induced by the inactivation of RASSF1A tumor-suppressor gene in lung cancer cells.

Keller M, Dubois F, Teulier S, Martin APJ, Levallet J, Maille E, Brosseau S, Elie N, Hergovich A, Bergot E, Camonis J, Zalcman G, Levallet G.

J Exp Clin Cancer Res. 2019 Apr 12;38(1):158. doi: 10.1186/s13046-019-1145-8.

3.

Nivolumab-refractory patients with advanced non-small-cell lung cancer.

Costantini A, Fallet V, Corny J, Friard S, Chouaid C, Duchemann B, Giroux-Leprieur E, Taillade L, Doucet L, Brosseau S, Wislez M, Tredaniel J, Cadranel J.

Lung Cancer. 2019 Apr;130:128-134. doi: 10.1016/j.lungcan.2019.01.015. Epub 2019 Feb 14.

PMID:
30885333
4.

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.

Maille E, Brosseau S, Hanoux V, Creveuil C, Danel C, Bergot E, Scherpereel A, Mazières J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Langlais A, Morin F, Levallet G, Zalcman G.

Br J Cancer. 2019 Feb;120(4):387-397. doi: 10.1038/s41416-019-0379-8. Epub 2019 Feb 11.

PMID:
30739911
5.

Safe and effective use of nivolumab for treating lung adenocarcinoma associated with sporadic lymphangioleiomyomatosis: a rare case report.

Pluvy J, Brosseau S, Stelianides S, Danel C, Nguenang M, Khalil A, Crestani B, Zalcman G, Gounant V.

BMC Pulm Med. 2019 Jan 11;19(1):12. doi: 10.1186/s12890-018-0775-5.

6.

Management of immune-related adverse events resulting from immune checkpoint blockade.

Baroudjian B, Arangalage D, Cuzzubbo S, Hervier B, Lebbé C, Lorillon G, Tazi A, Zalcman G, Bouattour M, Lioté F, Gautier JF, Brosseau S, Lourenco N, Delyon J; PATIO group.

Expert Rev Anticancer Ther. 2019 Mar;19(3):209-222. doi: 10.1080/14737140.2019.1562342. Epub 2019 Jan 9.

PMID:
30572735
7.

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.

Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C.

JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676.

PMID:
30193240
8.

(J)ALEX the great: a new era in the world of ALK inhibitors.

Brosseau S, Gounant V, Zalcman G.

J Thorac Dis. 2018 Jul;10(Suppl 18):S2138-S2143. doi: 10.21037/jtd.2018.06.142. No abstract available.

9.

Minimal Change Disease Induced by Lorlatinib.

Betton M, Gounant V, Sannier A, Hanouna G, Goujon JM, Brosseau S, Zalcman G, Chemouny JM.

J Thorac Oncol. 2018 Aug;13(8):e154-e156. doi: 10.1016/j.jtho.2018.03.033. No abstract available.

PMID:
30049381
10.

Xanthogranulomatous pyelonephritis complicating crizotinib treatment of an ALK-rearranged non-small-cell lung cancer.

Brosseau S, Gounant V, Choudat L, Pluvy J, Zalcman G, Khalil A.

Diagn Interv Imaging. 2018 Apr;99(4):267-268. doi: 10.1016/j.diii.2018.01.008. Epub 2018 Feb 19. No abstract available.

11.

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B.

JAMA Oncol. 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771.

12.

Immunotherapy in relapsed mesothelioma.

Brosseau S, Dhalluin X, Zalcman G, Scherpereel A.

Immunotherapy. 2018 Feb;10(2):77-80. doi: 10.2217/imt-2017-0144. No abstract available.

13.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.

Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.

PMID:
29097494
14.

A review of bevacizumab in the treatment of malignant pleural mesothelioma.

Brosseau S, Assoun S, Naltet C, Steinmetz C, Gounant V, Zalcman G.

Future Oncol. 2017 Dec;13(28):2537-2546. doi: 10.2217/fon-2017-0307. Epub 2017 Sep 20. Review.

PMID:
29086616
15.

Lazarus Syndrome With Crizotinib in a Non-Small Cell Lung Cancer Patient With ROS1 Rearrangement and Disseminated Intravascular Coagulation.

Brosseau S, Gounant V, Naltet C, Théou-Anton N, Cazes A, Smonig R, Neuville M, Khalil A, Mikail N, Meignin V, Bergeron A, Zalcman G.

Clin Lung Cancer. 2018 Jan;19(1):e57-e61. doi: 10.1016/j.cllc.2017.07.003. Epub 2017 Aug 3. No abstract available.

PMID:
28844392
16.

Bevacizumab in advanced lung cancer: state of the art.

Assoun S, Brosseau S, Steinmetz C, Gounant V, Zalcman G.

Future Oncol. 2017 Dec;13(28):2515-2535. doi: 10.2217/fon-2017-0302. Epub 2017 Aug 16. Review.

PMID:
28812378
17.

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.

Tomasini P, Brosseau S, Mazières J, Merlio JP, Beau-Faller M, Mosser J, Wislez M, Ouafik L, Besse B, Rouquette I, Debieuvre D, Escande F, Westeel V, Audigier-Valette C, Missy P, Langlais A, Morin F, Moro-Sibilot D, Zalcman G, Barlesi F.

Eur Respir J. 2017 Aug 10;50(2). pii: 1700514. doi: 10.1183/13993003.00514-2017. Print 2017 Aug.

18.

Lazarus syndrome in nonsmall cell lung cancer patients with poor performance status and major leukocytosis following nivolumab treatment.

Pluvy J, Brosseau S, Naltet C, Opsomer MA, Cazes A, Danel C, Khalil A, Zalcman G, Gounant V.

Eur Respir J. 2017 Jul 27;50(1). pii: 1700310. doi: 10.1183/13993003.00310-2017. Print 2017 Jul. No abstract available.

19.

[Current knowledge on perioperative treatments of non-small cell lung carcinomas].

Brosseau S, Naltet C, Nguenang M, Gounant V, Mordant P, Milleron B, Castier Y, Zalcman G.

Rev Mal Respir. 2017 Jun;34(6):618-634. doi: 10.1016/j.rmr.2016.12.001. Epub 2017 Jul 12. Review. French.

PMID:
28709816
20.

[Therapeutic advances in lung cancer].

Brosseau S, Naltet C, Gounant V, Zalcman G.

Rev Prat. 2017 Jan;67(1):47-50. French.

PMID:
30512433
21.

MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.

Levallet G, Dubois F, Fouret P, Antoine M, Brosseau S, Bergot E, Beau-Faller M, Gounant V, Brambilla E, Debieuvre D, Molinier O, Galateau-Sallé F, Mazieres J, Quoix E, Pujol JL, Moro-Sibilot D, Langlais A, Morin F, Westeel V, Zalcman G.

Oncotarget. 2017 Jan 17;8(3):4313-4329. doi: 10.18632/oncotarget.14025.

22.

[Prophylactic radiotherapy for procedure-tracts metastases in pleural mesothelioma: A phase 3 trial, "SMART"… not enough].

Brosseau S, Naltet C, Gounant V, Zalcman G.

Rev Mal Respir. 2016 Oct;33(8):654-657. doi: 10.1016/j.rmr.2016.10.005. French. No abstract available.

PMID:
27968925
23.

Prophylactic radiotherapy to prevent procedure-tract metastases.

Zalcman G, Brosseau S, Scherpereel A.

Lancet Oncol. 2016 Oct;17(10):e417. doi: 10.1016/S1470-2045(16)30387-4. No abstract available.

PMID:
27733263
24.

Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma.

Gounant V, Brosseau S, Naltet C, Opsomer MA, Antoine M, Danel C, Khalil A, Cadranel J, Zalcman G.

Lung Cancer. 2016 Sep;99:162-5. doi: 10.1016/j.lungcan.2016.07.010. Epub 2016 Jul 15.

PMID:
27565934
25.

Pulmonary complications of type 1 neurofibromatosis.

Reviron-Rabec L, Girerd B, Seferian A, Campbell K, Brosseau S, Bergot E, Humbert M, Zalcman G, Montani D.

Rev Mal Respir. 2016 Jun;33(6):460-73. doi: 10.1016/j.rmr.2014.09.010. Epub 2016 Feb 8. Review.

PMID:
26868668
26.

[Malignant pleural mesothelioma: rare and aggressive but with new therapeutic perspectives].

Brosseau S, Naltet C, Gounant V, Zalcman G.

Rev Prat. 2016 Feb;66(2):191-197. French.

PMID:
30512336
27.

Pre-Emptive or Reactive Treatment of Cutaneous Rash Induced by Epidermal Growth Factor Receptor Inhibitors: Does It Matter?

Zalcman G, Brosseau S, Gounant V.

J Clin Oncol. 2016 Mar 10;34(8):774-6. doi: 10.1200/JCO.2015.64.7529. Epub 2015 Dec 28. No abstract available.

PMID:
26712233
28.

[3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance].

Brosseau S, Viala M, Varga A, Planchard D, Besse B, Soria JC.

Bull Cancer. 2015 Sep;102(9):749-57. doi: 10.1016/j.bulcan.2015.05.001. Epub 2015 Jul 30. Review. French.

PMID:
26235419
29.

[Resistances to targeted therapies and strategy for following therapeutic lines in metastatic NSCLC].

Brosseau S, Oulkhouir Y, Naltet C, Zalcman G.

Bull Cancer. 2015 Jun;102(6 Suppl 1):S27-33. doi: 10.1016/S0007-4551(15)31215-7. Review. French.

PMID:
26118873
30.

[Second generation ALK inhibitors in non-small cell lung cancer: systemic review].

Viala M, Brosseau S, Planchard D, Besse B, Soria JC.

Bull Cancer. 2015 Apr;102(4):381-9. doi: 10.1016/j.bulcan.2015.02.016. Epub 2015 Mar 25. Review. French.

PMID:
25819217
31.

[Malignant pleural mesothelioma: 2013 state of the art].

Campbell K, Brosseau S, Reviron-Rabec L, Bergot E, Lechapt E, Levallet G, Zalcman G.

Bull Cancer. 2013 Dec;100(12):1283-93. doi: 10.1684/bdc.2013.1857. Review. French.

PMID:
24225007
32.

How to perform a thyroidectomy in an outpatient setting.

Champault A, Vons C, Zilberman S, Labaille T, Brosseau S, Franco D.

Langenbecks Arch Surg. 2009 Sep;394(5):897-902. doi: 10.1007/s00423-009-0527-3. Epub 2009 Jul 3.

PMID:
19575215

Supplemental Content

Loading ...
Support Center